新型非侵入性结直肠肿瘤筛查试验的成本效益
本研究用10年马尔可夫模型模拟45岁及以上平均风险人群的结直肠癌筛查,比较mt-sRNA(ColoSense)、两种mt-sDNA(Cologuard和Cologuard Plus)、血液cfDNA(Shield)与FIT。结果显示FIT在所有依从性水平下最具成本效益;在60%真实依从性下,mt-sRNA临床获益最大,且在三年度分子检测中成本效益最优。
要点
- 在分子检测中,mt-sRNA检测出的进展期腺瘤最多、转诊监测人数最多,预防的结直肠癌病例和死亡数最高。
- 60%真实依从性下,mt-sRNA较FIT降低结直肠癌病例1%、死亡14%;较mt-sDNA降低病例21%、死亡19%。
- FIT(25美元/次)在所有依从性水平下最具成本效益;三年度分子检测(509美元/次)中mt-sRNA最具成本效益。
核心结论
- FIT是预防结直肠癌病例和死亡最具成本效益的策略。
- 在60%真实依从性下,mt-sRNA表现出最大的临床获益,且比其他分子策略更具成本效益。
研究设计与样本
- 采用10年马尔可夫模型模拟疾病进展,比较mt-sRNA(ColoSense)、两种mt-sDNA(Cologuard和Cologuard Plus)、血液cfDNA(Shield)与FIT。
- 临床输入采用独立研究中年龄加权的灵敏度和特异度。
- 结局与结肠镜筛查方案及不筛查进行比较,模型校准和验证使用既往报道的癌症干预监测建模网络(CISNET)模型。
主要发现
- 在分子检测中,mt-sRNA检测出的进展期腺瘤最多,转诊监测人数最多,预防的结直肠癌病例和死亡数最高。
- 在60%真实依从性下,mt-sRNA较FIT降低结直肠癌病例1%、死亡14%。
- 在60%真实依从性下,mt-sRNA较mt-sDNA降低结直肠癌病例21%、死亡19%;较mt-sDNA+降低病例28%、死亡23%;较cfDNA降低病例80%、死亡86%。
- 相对于mt-sRNA方案,预防一例结直肠癌病例的成本:mt-sDNA高30%、mt-sDNA+高45%、cfDNA高642%。
- 相对于mt-sRNA方案,预防一例结直肠癌死亡的成本:mt-sDNA高30%、mt-sDNA+高41%、cfDNA高1040%。
关键数值与推荐
- FIT(25美元/次)在所有依从性水平下均为最具成本效益的策略。
- 三年度分子检测(509美元/次)中,mt-sRNA为最具成本效益的策略。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: This study assessed the economic and health impact of colorectal cancer (CRC) screening programs for average-risk individuals aged 45 years and older. METHODS: A 10-year Markov model simulated disease progression, comparing multitarget stool RNA test (mt-sRNA, ColoSense), two mt-sDNA tests (Cologuard and Cologuard Plus), a blood-based test (cfDNA, Shield), and a fecal immunochemical test (FIT). Clinical inputs leveraged age-weighted sensitivity and specificity from independent studies. Outcomes were compared with a colonoscopy-based program and no screening. Model calibration and validation used previously reported Cancer Intervention Surveillance Modeling Network (CISNET) models. RESULTS: Among molecular tests, mt-sRNA detected the most advanced adenomas, referred the most individuals to surveillance, and prevented the highest number of CRC cases and deaths. At real-world adherence of 60%, mt-sRNA reduced CRC cases and deaths by 1% and 14% compared with FIT; by 21% and 19% compared with mt-sDNA; by 28% and 23% compared with mt-sDNA+; and by 80% and 86% compared with cfDNA. For all adherence levels, FIT ($25/test) was the most cost-effective strategy. For triennial molecular tests ($509/test), mt-sRNA was the most cost-effective strategy. Relative to the mt-sRNA program, the cost to prevent a CRC case was 30% (mt-sDNA), 45% (mt-sDNA+), and 642% (cfDNA) more expensive. Relative to the mt-sRNA program, the cost to prevent a CRC death was 30% (mt-sDNA), 41% (mt-sDNA+), and 1040% (cfDNA) more expensive. CONCLUSIONS: FIT was the most cost-effective strategy for preventing CRC cases and deaths. At real-world adherence of 60%, mt-sRNA demonstrated the greatest clinical benefit and was more cost-effective than other molecular strategies.
引用
- Shaukat A, Levin TR, Liang PS, et al. Cost-Effectiveness of Novel Noninvasive Screening Tests for Colorectal Neoplasia. Clin Gastroenterol Hepatol. 2025. PMID: 40562290. doi:10.1016/j.cgh.2025.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。